Loading viewer...
investor_presentation
Format: PDF investor_presentation
MindMed is a neuro-pharmaceutical company developing psychedelic-inspired medicines, with lead candidates MM120 (lysergide D-tartrate) and MM402 (R(-)-MDMA) targeting brain health conditions. The company has a diversified clinical pipeline, substantial cash runway through 2027, and experienced management focused on regulatory approval and market protection strategies.
investor_presentation
Astral Resources NL
investor_presentation
36 Pages
Hillcrest Energy Technologies 2023 Investor Presentation
investor_presentationinvestor_presentation
21 Pages
Hillcrest Energy Technologies Ltd.
investor_presentation
Macroblock